What is TYRA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.37B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TYRA?

P/E (TTM) is n/a and 52-week range is $13.29 to $40.65 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TYRA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TYRA?

The company profile lists net income (TTM) near $-142M, EPS (TTM) near $-2.39 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Tyra Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Carlsbad, California, US, 59.5M shares outstanding, ISIN US90240B1061 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Tyra Biosciences Inc

$TYRA

Health Care · Biotechnology

IR Run Scenarios

$19.94

-0.15%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company is headquartered in Carlsbad, California and currently employs 87 full-time employees. The company went IPO on 2021-09-15. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. The company has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. The company is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

Employees

Website

tyra.bio/

IPO

2021-09-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)